- | Teclison
Teclison Closes $5.9M Funding Round
Teclison, a Princeton, NJ-based clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity, closed a $5.9m funding round.
- | Check-Cap
FDA approves IDE application for novel polyp detection test
The FDA has granted investigational device exemption to medical diagnostics company Check-Cap for a two-part pivotal study to evaluate C-Scan, a new screening test that detects precancerous polyps.
- | Scynexis
Ibrexafungerp shows promise against recurrent vulvovaginal candidiasis in phase 3 trial
There are currently no approved treatments for the prevention of recurrent VVC, but Scynexis said it will submit the new phase 3 data to the FDA in the first half of 2022 and expects that ibrexafungerp tablets will be approved for this indication by the end of the year.
- | Check-Cap
Ingestible Capsule Aims to Make Colon Cancer Screening Less Invasive
Cancer intervention and prevention company Check Cap is developing new, low-invasive ingestible capsule technology that aims to address issues associated with preventive screenings for colonoscopies.
- | Anixia Biosciences
Developing Prophylactic Cancer Vaccine to Attack Breast Cancer and Other Solid Tumors with Amit Kumar Anixa Biosciences
Amit Kumar is the President and CEO of Anixa Biosciences and is working on a prophylactic vaccine to prevent the onset of breast cancer rather than a therapeutic vaccine to fight the solid tumors. Anixa is also working on CAR-T therapy for solid tumors and using artificial intelligence and machine learning to discover compounds to treat COVID-19.
- | TFF Pharmaceuticals
From Zero to Hero: Biopharma’s Pivotal Inflection Point
As Glenn Mattes, CEO of TFF Pharmaceuticals, told BioSpace, “The persistent rise of COVID-19 cases, including among the vaccinated, has understandably impacted the morale of both the biopharma industry and the broader community.”
- | MeiraGTx
MeiraGTx Gets $30M Milestone Payment From Janssen Pharmaceuticals
MeiraGTx Holdings PLC said it received a $30 million payment from Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Cos. of Johnson & Johnson, for a clinical milestone in a Phase 3 trial of botaretigene sparoparvovec.
- | MindMed
FDA Clears Phase 2B Study Testing LSD for Anxiety
The US Food and Drug Administration has cleared an Investigational New Drug application allowing MindMed to move forward with a phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder (GAD).
